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ABSTRACT: A generic strategy to expand the analytical scope
of electrical nanopore sensing is presented. We speciﬁcally and
electrically detect the activity of a diagnostically relevant
hydrolytic enzyme and remove the analytically harmful
interference from the biochemically complex sample matrix of
blood serum. Our strategy is demonstrated at the example of the
renin protease which is involved in regulation of blood pressure.
The analysis scheme exploits a new approach to reduce sample
complexity while generating a speciﬁc read-out signal. Within a single spin-column (i), the protease cleaves a resin-tethered
peptide substrate (ii) which is aﬃnity-puriﬁed using the same multifunctional resin to remove interfering blood serum
components, followed by (iii) detecting the peptide via electrical nanopore recordings. Our approach is beneﬁcial in several ways.
First, by eliminating serum components, we overcome limitations of nanopore sensing when challenging samples lead to
membrane instability and a poor signal-to-noise ratio. Second, the label-free sensing avoids drawbacks of currently used
radiolabel-immunoassays for renin. Finally, the strategy of simultaneous generation and puriﬁcation of a signal peptide within a
multifunctional resin can very likely be expanded to other hydrolytic enzymes dissolved in any analyte matrix and exploited for
analytical read-out methods other than nanopore sensing.
Nanopore analytics is an increasingly popular approach todetect molecules in a label-free fashion. The sensing
principle with nanopores is simple yet powerful. Individual
molecules pass through or interact with a single pore of
nanoscale diameter thereby causing detectable changes in ionic
pore current (Figure 1A).1−3 Detecting individual molecules
has advantages over ensemble measurements. For example,
subpopulations of analytes can be uncovered as well as the
molecules’ shape, size, or net charge. The approach is generic
and can be implemented with diﬀerent types of nanopores.
These include biological protein pores embedded into a lipid
bilayer as well as with man-made solid-state pores drilled into
thin membranes composed of SiN, glass, or organic polymers.1
Reﬂecting its generic principle, nanopore analytics can be
exploited for the speciﬁc and label-free sensing of nucleic
acid4−8 including DNA sequencing,9,10 the detection of
proteins,11−14 and enzymatic activity and peptides,15−19 which
are of relevance to the present report.5
Despite the advances, sensing of analytes in biological
samples with a complex analyte matrix remains challenging.
One issue is the often dramatic increase in the background
signal triggered by nonanalyte molecules of the matrix which
unspeciﬁcally block the nanopore, as schematically illustrated in
Figure 1B. This is of particular importance for pores without
analyte receptors as these help enhance the strength of the
speciﬁc signal.20,21 Another problem is the instability of lipid
bilayers which are disrupted by amphiphilic proteins22,23 found,
e.g., in blood-derived samples (Figure 1B). Lipid bilayers can be
physically stabilized23 but remain biochemically labile. Another
possible route is to replace biological pores with inert solid-
state nanopore membranes.1,24−26 However, the diameter of
these pores is usually too wide for relatively small peptide
analytes,27,28 and peptide detection based on ionic current
blockades has, to our knowledge, not been experimentally
achieved with solid-state pores. Protein or DNA-origami pores
can be inserted into solid-state pores29,30 to narrow the eﬀective
pore diameter, but the higher noise level hinders the sensing of
very small analytes such as peptides.
Here, we present a new nanopore-based strategy to
speciﬁcally sense enzymatic activity present in a matrix
containing serum proteins. The approach combines several
beneﬁcial features and overcomes the issue of membrane
instability while maintaining sensitivity and reducing non-
speciﬁc background signal. The sensing strategy is exempliﬁed
at the biochemical analyte renin. Renin is a protease enzyme
which mediates the regulation of blood pressure and homeo-
stasis31 by generating peptide-based hormones via proteolysis.
The natural substrate of renin is the pro-hormone angiotensi-
nogen. Proteolytic cleavage by renin releases the biologically
active N-terminal 10 amino acid-long peptide angiotensin I
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which in turn can be fragmented into smaller hormones. Given
its role as signaling gate-keeper, renin activity in serum is a
useful clinical indicator of hypertension. Currently used
approaches to detect renin are based on radioactivity-based
immunoassays to either determine the amount of renin or
measure its activity via the proteolytically cleaved peptide
substrates.32−34 By comparison, our new nanopore-based
strategy is label-free and less complex. We demonstrate its
viability by detecting renin at high speciﬁcity and sensitivity. We
expect that the advantages of our analytical route are widely
applicable to sense several other hydrolytic enzymes in complex
sample matrices.
■ RESULTS AND DISCUSSION
The principle of the sensing strategy for renin features two
functional modules: signal generation and signal sensing. Both
are schematically illustrated in Figure 2A−C and Figure 2D,
respectively. Brieﬂy, signal generation is achieved by adding
renin-containing blood serum to microscale beads P displaying
a substrate peptide (Figure 2A) derived from angiotensinogen.
After renin-mediated cleavage, peptide fragment Ang-His6
(Figure 2A, indicated in red) binds with its engineered
hexahistidine tag speciﬁcally to Ni2+-NTA-beads, N, while
membrane-destabilizing serum proteins are removed by
washing (Figure 2B) so that puriﬁed peptide Ang-His6 can be
eluted (Figure 2C). The signal generation module hence
features a uniquely designed peptide substrate for surface-
tethered peptide cleavage and puriﬁcation using two types of
beads within a single spin column. This is novel and simpliﬁes
handling as signal generation can be carried out in a simple
fashion. In the subsequent module for signal sensing (Figure
2D), the eluted peptide fragments are detected as they pass a
protein nanopore and give rise to transient blockades in the
ionic pore current.
The substrate beads P were carefully designed to achieve
speciﬁc and eﬃcient cleavage by renin. The substrate peptide
HO-SHIV/LHFPHIYVRD-HHHHHH-NH2 (Figure 2, cleav-
age site indicated by a slash) was derived from the N-terminus
of angiotensinogen.35 The underlined substrate sequence
(corresponding to amino acid position 14 to 1 of
angiotensinogen35,36) is long enough to ensure speciﬁc
recognition by renin without interference by the engineered
His6 tag at the peptide’s N terminus.
37−39 To further improve
steric accessibility, the peptide was C-terminally linked to beads
via a ﬂexible polyethylene glycol-based linker.40 Steric
accessibility to the peptide substrate was also designed to be
high as the beads were composed of polyacrylamide which can
swell in water to permit the permeation by proteins with a mass
of up to 35 kDa which includes renin.41
The tethered substrate was speciﬁcally recognized and
cleaved by renin as shown by HPLC analysis of the released
soluble Ang-His6. For reasons of simplicity, the digestion was
conducted ﬁrst with isolated beads P and renin but in the
absence of serum components or beads N. The HPLC traces of
the supernatants of the cleavage mixtures (Figure 3A) feature a
unique peak at 16 min which increases in magnitude with
longer incubation times (Figure 3A, B). The peak represents
soluble Ang-His6 fragment released by renin activity, as
conﬁrmed by mass spectrometry (see the Supporting
Information). In control experiments, no peptide peak was
observed in the absence of renin or when the non-recognizing
enzyme trypsin was used (data not shown) conﬁrming the
speciﬁcity of the renin-mediated cleavage. The second major
peak in the kinetic HPLC traces at 20 min (Figure 3B)
represents protein BSA which is included to stabilize renin. We
note that incubation durations of several hours to overnight are
common for the existing renin assays.32−34
Figure 1. Scheme illustrating the principle and challenges of electrical
nanopore sensing. (A) The sensing approach relies on the trans-
location of target analytes through a lipid bilayer-embedded nanopore
giving rise to time-dependent blockades of the ionic pore current, I.
(B) Undesired background signals are caused by nontarget molecules
in the sample (top). Components of the analyte matrix such as serum
proteins rupture the bilayer membrane (bottom).
Figure 2. Scheme illustrating the sensing strategy for the protease
renin. It involves (A) the enzymatic cleavage of the substrate peptide
fragment Ang-His6 (red) from beads P and simultaneous aﬃnity
binding to beads N carrying Ni2+-NTA groups, (B) removal of serum
proteins by washing, (C) elution of the Ang-His6 peptide, and (D)
electrical sensing of the peptide using the membrane nanopore α-
hemolysin. Steps A−C are conducted using one spin column
containing a mixture of beads P and N.
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The enzymatically derived Ang-His6 solutions were analyzed
with nanopore recordings (i) to establish that the peptide
solutions give rise to clear current electrical signals. Additional
objectives were (ii) to conﬁrm the signals’ molecular origin by
comparison to synthetic peptide analogues and (iii) to
demonstrate that increasing peptide concentrations from a
longer enzyme incubation lead to more frequent signals. The
electrical recordings were conducted with the α-hemolysin
(αHL) protein pore (Figure 2D) which is of known X-ray
structure42 and widely used in nanopore analytics.1 A single
αHL nanopore was inserted in a lipid bilayer, and electrical
nanopore recordings were performed using standard electrolyte
conditions (1 M KCl and 50 mM Tris, pH 8.2). Flow of ionic
current was induced by applying a potential of +100 mV at the
trans side of the αHL pore with the cis side grounded (Figure
2D). At these conditions, the αHL pore displayed a current of
105.4 ± 6.6 pA (Figure 4A, 0 min) (n = 10; n, number of
independent recordings). Addition of the peptide solution to
the cis side caused short current blockades (Figure 4A; 5 min, 4
h, 24 h). The clear current signals (Figure 4B) most likely
represent the translocation of individual peptides from the cis to
the positively polarized trans side of the pore. The signals do
not stem from BSA as the protein with dimensions of
approximately 6 × 5 × 4 nm cannot enter the 2.9 nm-wide
cis pore entrance. Indeed, control recordings with a BSA
solution did not give rise to blockades found for Ang-His6 (data
not shown).
We characterized the blockades’ average amplitude, A, and
duration, τoff, and compared them to signals obtained for the
synthetically derived peptide fragment Ang-His6. The param-
eters A and τoff are deﬁned in Figure 4B, and the corresponding
histograms for the analysis are shown in the Supporting
Information, Figure S1. The amplitude of the enzyme-released
peptide had a magnitude of 81.6 ± 2.6% (n = 3) of the open
channel. This is close to A for the synthetic Ang-His6 (78.6 ±
2.5%, n = 4; Supporting Information, Figure S2) and also
within the data range found for other short oligopepti-
des.17,18,43−45 Similarly, the distribution of the amplitudes in
the single-channel histograms was wide (Supporting Informa-
tion, Figure S2), as would be expected for conformationally
ﬂexible peptides, compared to the narrow distribution of DNA
strands.46−48 The value for τoff with 0.62 ± 0.18 ms was within
the margin of error for the synthetic peptide, 1.02 ± 0.32 ms
(Supporting Information, Figure S2), and in line with the time
scales for the translocation of other peptides.17,18,43−45
The frequencies of occurrence of the electrical signals for the
enzymatically released Ang-His6 (Figure 4A) were determined
and compared to the kinetic HPLC data. The frequencies are
obtained from the inverse of the characteristic inter-event
interval, τon (Figure 4C). In line with expectations, more
frequent current blockades were observed for higher peptide
concentrations from longer renin incubation times resulting in
a good correlation between both data sets (Supporting
Information, Figure S1A, Table S1). For example, the
frequency of occurrence increased from 0.02 ± 0.009 s−1 at a
5 min incubation approximately 20-fold to 0.39 ± 0.04 s−1 at 24
h. Importantly, the frequencies of the enzymatically released
Ang-His6 were comparable in value to the synthetic peptide
once normalized to the corresponding peptide concentrations
in the electrolyte solution of the recording chamber. For
example, the signal for the sample with a 24 h incubation had a
frequency of 0.08 ± 0.02 s−1 μM−1 which is close to the value of
0.10 ± 0.03 s−1 μM−1 (n = 3) for the synthetic peptide.
We note that the signal frequency can be increased by tuning
experimental parameters such as electrolyte gradient and larger
transmembrane voltage. Both factors can enhance the electro-
phoretic channeling of peptides into the pore. The eﬀect of the
Figure 3. Renin cleaves peptide fragment Ang-His6 from beads P as
shown by HPLC analysis. (A) HPLC traces of digestion solutions
incubated for the indicated durations. Beads P were removed prior to
analysis of the sample. (B) The area of the Ang-His6 peak at 16 min
retention time increases with the duration of the enzymatic digestion.
The peak area was normalized to the BSA peak with a retention time
of 20 min. The data represent the averages of two independent
experiments.
Figure 4. Peptide Ang-His6 causes clear current blockades in nanopore
recordings. (A) Single-channel current traces of the αHL pore without
peptide (0 min) and with peptide solution from the renin-digestion of
Figure 3 for the indicated durations. The latter traces were acquired in
the variable-length mode of nanopore acquisition software pClamp
and subjected to data reduction. In variable-length mode, segments of
the trace without blockade events are removed to yield a concatenated
series of blockades. Events with an amplitude of 25% or higher were
included. The three traces display events recorded within 100 s which
is diﬀerent from the duration of the concatenated event segments. (B)
An individual current blockade event with duration τoﬀ and amplitude
A deﬁned by the diﬀerence between the open-channel current, Io, and
the current level for the blocked channel, Ib. (C) The interevent
interval, τon, between separate currents is used to calculate their
frequency of occurrence, f, using f = 1/τon.
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gradient across the bilayer is mediated via magniﬁed electric
ﬁeld and was pioneered for DNA strands.49 When adapted to
the synthetic Ang-His6 peptide, the salt gradient of 0.2 M cis/
3.8 M KCl trans resulted in a 3.9-fold increase of the signal
frequency to a value of 0.39 ± 0.07 s−1 μM−1 (n = 3) compared
to symmetric conditions at 1 M KCl. The eﬀect is smaller than
previously observed for DNA but in line with the lower charge
density (isoelectric point of 7.28) and smaller electrophoretic
force for the peptide. The signal frequency was further boosted
2.5-fold by doubling the transmembrane voltage from 100 to
200 mV. Hence, both salt gradient and a higher potential raised
the signal frequency approximately 10-fold from 0.10 ± 0.03 to
1.03 ± 0.22 s−1 μM−1 (n = 3). This increase is of interest when
attempting to further increase the sensitivity of the electrical
recordings.
After detecting renin activity via cleaved peptides and
nanopores read-out, we next probed whether the sensing
approach can be applied to renin within human blood serum.
We spiked the serum with renin and incubated the mixture with
angiotensinogen-His6 carrying beads and Ni
2+-NTA carrying N-
beads. As schematically illustrated in Figure 2A−C, this
procedure is expected to achieve renin-mediated cleavage of
fragment Ang-His6 as well as the fragment’s binding via the
His6-tag to the Ni
2+‑NTA-beads. Washing is expected to lead to
removal of the serum proteins. In contrast, Ang-His6 can later
be released from the N-beads by elution with imidazole which
competes for binding in the metal chelate bridge with histidine.
The procedure successfully eliminated the majority of the
serum protein content, as shown by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis for
the sample before (Figure 5A, lane SAM) and after puriﬁcation
(Figure 5A, EL1). The eﬀective removal was most drastic for
albumin with a molecular weight of around 65 kDa (Figure
5A). Quantitative analysis via the Bradford protein assay
established that the puriﬁcation procedure lowered the protein
content over 300-fold from 140.3 to 0.47 mg mL−1.
Complementary HPLC analysis of the eluate conﬁrmed that
the cleaved substrate fragment Ang-His6 was successfully eluted
(Figure 5B; trace Ang-H6, el.). As expected for speciﬁc cleavage,
the HPLC peak eluted at the same position as synthetic Ang-
His6 (Figure 5B; Ang-H6 syn). Furthermore, renin rather than
nonspeciﬁc hydrolysis caused fragmentation, as illustrated by a
control experiment without enzyme but with serum (Figure 5B,
blank). It is also certain that the eluted peptide peak solely
represents Ang-His6 rather than any other peptides such as the
substrate angiotensinogen-His6 as both synthetic peptides have
diﬀerent HPLC retention times (Figure 5B, Ang-His6 and A-
His6). MALDI MS analysis conﬁrmed the expected chemical
identity of the Ang-His6 peak (Supporting Information, Figure
S5). HPLC analysis of the peak areas furthermore quantiﬁed
the amount of Ang-His6 peptide puriﬁed with N-beads using a
calibration curve setup using the synthetic peptide of known
concentration to provide a reference standard for comparison
to nanopores recordings.
The presence of the Ang-His6 peptide in the solution was
conﬁrmed by nanopore recordings. The current blockades
obtained when adding the eluate to the cis side of the αHL pore
(Figure 6A) had an average blockade amplitude of 76 ± 4% and
duration of 0.68 ± 0.22 ms (n = 4) (Supporting Information,
Figure S3) consistent with the characteristics of events
previously obtained for synthetic as well as enzymatically
released but unpuriﬁed peptide. Furthermore, the frequency of
occurrence for the puriﬁed peptides was 0.12 ± 0.03 s−1 μM−1
after normalization to the peptide concentration obtained from
HPLC analysis. This frequency of occurrence is in good
agreement with the value obtained for recordings with the
reference standard of the synthetic peptide 0.10 ± 0.03 s−1
μM−1. Nanopore recordings ﬁnally established that the
presence of serum protein in unpuriﬁed samples lead to
rupturing of the lipid bilayer membranes (Supporting
Information, Figure S4), thereby underscoring the necessity
to remove the destabilizing proteins in order to conduct
successful nanopores measurements.
Figure 5. Renin-mediated liberation of Ang-His6 and puriﬁcation from
serum proteins using one column containing beads P and N. (A) SDS
polyacrylamide electropherogram illustrating the removal of serum
proteins. The lanes show the initial sample (SAM), fractions after
column washes with water (W1−3 and W6−7) and 10 mM imidazole-
containing buﬀer (IW1 and IW4), and eluates using 250 mM
imidazole solution (EL1−4). The position of the molecular weight
markers in kDa is indicated at the right side of the gel image. (B)
HPLC traces of the EL1 eluate stemming from the digestion/
puriﬁcation protocol (Ang-H6, el.), a control without renin (Blank), a
synthetic version of the peptide cleavage product (Ang-H6, syn.), and a
mixture of synthetic peptide Ang-His6 and substrate angiotensinogen
(Ang-H6 and A-H6).
Figure 6. Ang-His6 peptide that has been cleaved by renin and puriﬁed
from serum proteins leads to blockade events of the αHL pore. The
analyzed sample is the EL1 eluate from Figure 5. The nanopore
recording was obtained in the variable-length mode where segments of
the trace without blockade events are removed to yield a concatenated
series of blockades. The threshold for including events was a blockade
amplitude of 25% or higher.
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Here, we have presented a new approach to detect hydrolytic
enzyme activity. The enabling core of the strategy is the use of a
rationally designed substrate in combination with solid-phase
digestion and puriﬁcation. The advantages of the approach
include the simpliﬁcation of sample processing, the facile
generation of a speciﬁc target signal, the simultaneous
reduction of background noise, and the removal of other
undesired contaminants which otherwise interfere with the
signal detection. The strategy was demonstrated for enzyme
renin but should in principle be applicable to all other
hydrolytic enzymes, including peptidases, protease, nucleases,
glyosylases, and other biopolymer-cleaving enzymes as well as
esterases, amidases, and enzymes that cleave bonds, provided
the chemical substrate is designed to facilitate solid-phase
digestion and puriﬁcation. Our strategy was exempliﬁed with
nanopore analysis but could be expanded to other read-out
techniques that beneﬁt from the simpliﬁcation of the sample
complexity.
■ EXPERIMENTAL SECTION
Synthesis of Soluble and Resin-Linked Peptides. The
soluble peptides angiotensinogen-His6 and angiotensin-His6
and PEGA resin-linked angiotensinogen-His6 were synthesized
using Fmoc solid-phase peptide synthesis as described in the
Supporting Information.
HPLC Analysis. HPLC analysis was performed using a
reverse phase Varian ProStar system with a Model 210 solvent
delivery mode and a Model 320 dual wavelength detector. The
mobile phase A consisted of 0.1% (v/v) TFA in water and
mobile phase B was 0.1% (TFA) in acteonitrile. The UV
absorbance was monitored at 214 and 254 nm. Analytical
analysis was performed using a Varian Pursuit XRS C18 column
(250 × 4.6 mm). The gradient started with 2% eluent B and
rose linearly to 60% B over 20 min with a ﬂow rate of 1 mL
min−1. Semipreparative puriﬁcation was performed using a
Phenomenex Luna C18 column (250 × 10 mm). The gradient
started with 2% eluent B and rose linearly to 60% B over 30
min with a ﬂow rate of 5 mL min−1. Fractions containing the
correct peak were pooled; the solvent was removed under
reduced pressure to approximately 1 mL, and the solution was
lyophilized overnight. The purity of the peptides was assessed
using analytical HPLC and MS analysis.
MS Analysis. ESI-MS analysis was performed using a
Waters Aquity Ultra performance LC-MS system equipped
with an Aquity UPLC BEH C18 column (50 × 2.1 mm, 1.7
mm beads). MALDI-MS analysis was performed using a Waters
Micro MX machine. For MALDI analysis, the peptides were
concentrated and desalted via aspiration through C18 Ziptip
tips (Millipore) and eluted using a 50% ACN solution. The
eluted peptides were mixed with an α-cyano-4-hydroxycin-
namic acid matrix and then spotted onto a MALDI plate. The
spots were allowed to dry prior to analysis.
Enzymatic Assays. Solid-Phase Digestion of Angiotensi-
nogen-His6-Beads in the Absence of Ni
2+-NTA Beads and
Serum. For the time-course experiments, 4 mg of dried resin
was suspended in 50 mM MOPS buﬀer (1400 μL, pH 6.8)
containing 0.18 mg mL−1 BSA. The suspension was
equilibrated at 37 °C for 1.5 h with gentle shaking to ensure
that the beads were swollen and dispersed. The reaction was
started by the addition of renin solution (5U, 0.2U/μL). At
regular intervals, 50 μL aliquots were withdrawn and
immediately chilled on ice and then stored at 4 °C prior to
HPLC, MS, or nanopore analysis. HPLC was used to determine
the degree of proteolysis. The HPLC peak areas of released
peptide were ﬁrst normalized to the peak area of BSA and
compared to a calibration curve. The quantity was corrected for
the change in the concentration of peptide and protein due to
the removal of aliquots in the assay.
Solid-Phase Digestion in the Presence of Human Serum
and Ni2+-NTA. An aliquot (200 μL) of the Ni2+-NTA
suspension (Qiagen) was centrifuged (10 min, 0.8 rpm) and
resuspended in ddH2O (1 mL). The beads were then washed
twice with sodium phosphate buﬀer (100 mM, pH 7.4, 0.19 mg
mL−1 BSA, 1 mL) using the same technique and then ﬁnally
resuspended in 400 μL of buﬀer. The Ni2+-NTA-bead
suspension was combined with PEGA-angiotensinogenH6
resin (4 mg) which had been washed. To the resultant
suspension, human serum (125 μL) was added followed by
renin solution (5U, 1.25U/μL). The mixture was incubated at
37 °C, with gentle shaking at 950 rpm for 18 h. The suspension
was transferred to a QiaShredder spin column (the inner
homogenizing frit removed) and centrifuged (30 s, 0.8 rpm) to
separate the supernatant. The beads were washed with ddH2O
(7 × 500 μL) and wash solution (10 mM imidazole, 300 mM
NaCl, 50 mM sodium phosphate, pH 7.99, 4 × 500 μL),
followed by treatment with elution solution (250 mM
imidazole, 200 mM NaCl, 50 mM sodium phosphate, pH
8.0, 4 × 500 μL). For these wash and elution steps, the beads
were incubated for 1 min under gentle shaking, before
centrifugation to collect each ﬁltrate in a fresh tube. The
eluted peptides were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), HPLC and
MALDI MS. For SDS-PAGE (12%), aliquots (10 μL) of each
sample were mixed with an equal volume of loading buﬀer and
run at 200 mV for 1 h. Gel bands were visualized by Coomassie
Blue G-250 staining. The protein concentration of the serum
was determined using the Bradford Protein Assay (Bio-Rad,
Hercules, CA). Bovine serum albumin was used to generate a
calibration curve. Each sample was analyzed in triplicate.
Similarly, the peptide concentration was determined by
integrating the peak areas in the HPLC chromatograms and
comparison to a calibration curve setup with synthetic Ang-His6
peptide. Two independent sample sets were analyzed.
Nanopore Recordings. Single-channel current recordings
were performed by using a planar lipid bilayer apparatus as
described.50 Brieﬂy, a bilayer of 1,2-diphytanoyl-sn-glycero-3-
phosphocholine (Avanti Polar Lipids) was formed on an
aperture (100 μm in diameter) in a Teﬂon septum (Goodfellow
Corporation) separating the cis and trans chambers of the
apparatus. Each compartment contained 1 M KCl, 50 mM Tris-
HCl, pH 8.2, except for recordings with a salt gradient. Gel-
puriﬁed heptameric αHL protein (ﬁnal concentration 0.01−0.1
ng mL−1) was added to the cis compartment to achieve
insertion of a single channel into the bilayer. Subsequently,
peptide-containing samples from the enzymatic digest or
synthetic version were added to the cis side. Transmembrane
currents were recorded at a holding potential of +100 mV (with
the cis side grounded), unless stated otherwise, by using a
patch−clamp ampliﬁer (Axopatch 200B, Axon Instruments,
Union City, CA). For analysis, currents were low-pass ﬁltered
at 10 kHz and sampled at 50 kHz using a Digidata 1200 A/D
converter (Axon Instruments), as described.12
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Experimental procedures for the synthesis of soluble and resin-
linked peptides, scientiﬁc data on the characterization of
nanopore current blockades caused by (i) Ang-His6 enzymati-
cally released by renin from P-beads, (ii) synthetic Ang-His6,
and (iii) Ang-His6 renin-cleaved from the P substrate beads and
concomitant His-tag-puriﬁcation, MALDI mass spectrum of
Ang-His6 after renin-digestion of P-beads and His-tag
puriﬁcation with N-beads, and a current trace of lipid bilayer
membrane showing rupture due to human serum protein. The
Supporting Information is available free of charge on the ACS
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